BridgeBio Pharma, Inc. Operating Income (Loss) in USD from 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BridgeBio Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to Q3 2025.
  • BridgeBio Pharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$145M, a 24.3% increase year-over-year.
  • BridgeBio Pharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$610M, a 12% decline year-over-year.
  • BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2024 was -$593M, a 2.37% increase from 2023.
  • BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2023 was -$607M, a 18.6% decline from 2022.
  • BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2022 was -$512M, a 11.2% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

BridgeBio Pharma, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$610M -$145M +$46.6M +24.3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-29
Q2 2025 -$656M -$134M +$41.3M +23.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 -$698M -$104M -$105M -30529% Jan 1, 2025 Mar 31, 2025 10-Q 2025-04-29
Q4 2024 -$593M -$226M -$48.6M -27.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-20
Q3 2024 -$544M -$192M -$34.1M -21.6% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-29
Q2 2024 -$510M -$176M -$29.4M -20.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 -$481M $343K +$127M Jan 1, 2024 Mar 31, 2024 10-Q 2025-04-29
Q4 2023 -$607M -$177M -$48.2M -37.3% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-20
Q3 2023 -$559M -$158M -$28.6M -22.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$531M -$146M -$65.9M -82.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$465M -$126M +$47.5M +27.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$512M -$129M +$36.4M +22% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-20
Q3 2022 -$549M -$129M +$20.4M +13.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$569M -$80.2M +$13.8M +14.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$583M -$174M -$6.17M -3.69% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$577M -$166M -$38.1M -29.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 -$539M -$149M -$29.6M -24.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$509M -$94M +$30.6M +24.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$539M -$168M -$65M -63.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$474M -$127M -$48.9M -62.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 -$426M -$120M -$65.4M -120% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$360M -$125M -$55.2M -79.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$305M -$102M -$38.7M -60.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$266M -$78.6M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 -$54.5M -$13.1M -31.5% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$69.3M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-11
Q1 2019 -$63.8M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q3 2018 -$41.5M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08

BridgeBio Pharma, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$593M +$14.4M +2.37% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-20
2023 -$607M -$95.2M -18.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-20
2022 -$512M +$64.4M +11.2% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-20
2021 -$577M -$102M -21.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$474M -$208M -78.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$266M -$82.6M -45% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$184M -$140M -319% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$43.9M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.